Sight Sciences Q4 revenue rises 7%

Sight Sciences

04/03/2026 21:38

Overview

Eyecare tech firm's Q4 revenue grew 7% yr/yr, meeting analyst expectations

Company reduced Q4 operating expenses by 25% yr/yr

2026 revenue expected to grow 6% to 14%

Outlook

Sight Sciences expects 2026 revenue between $82 mln and $88 mln, up 6% to 14%

Company forecasts Interventional Glaucoma revenue of $77 mln to $81 mln in 2026

Sight Sciences anticipates Interventional Dry Eye revenue of $5 mln to $7 mln in 2026

Result Drivers

INTERVENTIONAL GLAUCOMA - Revenue growth driven by higher average selling prices and increased ordering accounts

INTERVENTIONAL DRY EYE - Revenue increase due to higher average selling prices

EXPENSE REDUCTION - Operating expenses decreased 25% due to lower personnel-related expenses and stock-based compensation

Company press release: ID:nGNX3FHLNF

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Meet
$20.40 mln
$20.40 mln (7 Analysts)
Q4 EPS
-$0.08
Q4 Net Income
-$4.20 mln
Q4 Gross Margin
87.00%
Q4 Gross Profit
$17.80 mln
Q4 Operating Expenses
$21.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Sight Sciences Inc is $9.05, about 72.1% above its March 3 closing price of $5.26

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)